Advisory Committee

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA)

Retrieved on: 
Monday, January 24, 2022
Lasso, Alport syndrome, Patient, Alport, News, GPM, Kidney, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Advisory Committee, Safety, NASDAQ, GLOBE, Court, Time, Chronic kidney disease, Lists of schools in England, Risk, Food, AS, FDA, Defendant, DNA methylation, Trial of the century, Investment, Pharmaceutical industry, Animal

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Reata securities during the Class Period, you may move the Court no later than February 18, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marathon Digital, Redwire, Robinhood, and Reata Pharmaceuticals and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 24, 2022
New Drug Application, Alport syndrome, Patient, Alport, News, Week, Kidney, Disclosure, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glomerular filtration rate, Audit committee, NYSE, Advisory Committee, NASDAQ, Safety, Marathon, Trial of the century, GLOBE, Redwire, EGFR, Chronic kidney disease, Lists of schools in England, Company, RDW, Shareholder, Risk, Robinhood (company), Food, AS, P.C, FDA, Mission statement, Defendant, Reata Pharmaceuticals, Risk management, Cryptocurrency, Animal, Audit, Pharmaceutical industry, Robin Hood (disambiguation)

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.

Key Points: 
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • On this news, Marathons stock price fell $20.52 per share, or 27.03%, to close at $55.40 per share on November 15, 2021.
  • For more information on the Marathon Digital class action go to: https://bespc.com/cases/MARA
    On November 10, 2021, Redwire announced that it would postpone the release of its third quarter earnings results.
  • For more information on the Reata Pharmaceuticals class action go to: https://bespc.com/cases/RETA
    About Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Reata Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – RETA

Retrieved on: 
Sunday, January 23, 2022
Securities Exchange Act of 1934, New Drug Application, Alport syndrome, Patient, Alport, News, Week, Person, Kidney, Pomerantz, CKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glomerular filtration rate, Advisory Committee, Safety, NASDAQ, Ext, Company, Trial of the century, GLOBE, Lists of action films, Court, EGFR, Chronic kidney disease, Lists of schools in England, Complaint, Therapy, Risk, Food, AS, Defendant, FDA, District court, Reata Pharmaceuticals, Pharmaceutical industry, Animal

If you are a shareholder who purchased Reata securities, and/or sold Reata put options, during the Class Period, you have until February 18, 2022 to ask the Court to appoint you as Lead Plaintiff for the class.

Key Points: 
  • If you are a shareholder who purchased Reata securities, and/or sold Reata put options, during the Class Period, you have until February 18, 2022 to ask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Reata Pharmaceuticals, Inc. for Securities Fraud, Expanding the Class Period

Retrieved on: 
Friday, January 21, 2022
Alport syndrome, Alport, District council, Advisory Committee, NASDAQ, GLOBE, Citizen's Briefing Book, Chronic kidney disease, Therapy, Certification, FDA, Complaint, Reata Pharmaceuticals, Pharmaceutical industry, Online gambling

The complaint expands the class period that was asserted in a previously filed related securities class action pending against Reata captioned Doyle v. Reata Pharmaceuticals, Inc., No.

Key Points: 
  • The complaint expands the class period that was asserted in a previously filed related securities class action pending against Reata captioned Doyle v. Reata Pharmaceuticals, Inc., No.
  • ), and is brought on behalf of investors that incurred damages on their purchases in Reata common stock between November 14, 2016 and December 6, 2021, inclusive (the Class Period).
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the countrys financial markets.

Tom Chisholm, Fulcrum Partners a OneDigital Company, Accepted into Forbes Business Council

Retrieved on: 
Thursday, January 20, 2022
United States national team, Technology, Retirement, Accounting, SEC, Advisory Committee, YEC, LSF, FINRA, GLOBE, Forbes, VSI, Industry, Team, News, Form, The Business Council, VAI, LLC, SIPC, Organization, Partnership, Financial adviser, Insurance

ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Tom Chisholm , Vice President Retirement, Fulcrum Partners, a OneDigital Company, will continue his ongoing role as part of the Forbes Business Council for 2022.

Key Points: 
  • ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Tom Chisholm , Vice President Retirement, Fulcrum Partners, a OneDigital Company, will continue his ongoing role as part of the Forbes Business Council for 2022.
  • For the third consecutive year he will also be serving as part of Forbes Chicago Business Council.
  • The Forbes Business Council is widely viewed as one of the foremost growth and networking organizations for successful business owners and leaders worldwide, said Tom.
  • Scott Gerber, founder of Forbes Councils, the collective that includes Forbes Business Council, said, We are honored that Tom is continuing his role in the community.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Robinhood, Reata Pharmaceuticals, Desktop Metal, and Chegg and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, January 18, 2022
Securities Exchange Act of 1934, New Drug Application, Alport syndrome, Patient, Alport, News, Week, Kidney, Desktop Metal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Glomerular filtration rate, NYSE, Advisory Committee, NASDAQ, Safety, Growth, Trial of the century, Student, Solution, GLOBE, EnvisionTEC, EGFR, Chronic kidney disease, Lists of schools in England, Company, Shareholder, Risk, Robinhood (company), Food, AS, P.C, FDA, Defendant, DM, Reata Pharmaceuticals, Complaint, Cryptocurrency, Audit, Pharmaceutical industry, Animal, 3D printing, Robin Hood (disambiguation), Chegg

On July 30, 2021, Robinhood conducted its initial public offering (IPO), issuing 55 million shares priced at $38.00 per share.

Key Points: 
  • On July 30, 2021, Robinhood conducted its initial public offering (IPO), issuing 55 million shares priced at $38.00 per share.
  • On this news, Robinhoods stock price fell $4.13 per share, or 10.44%, to close at $35.44 per share on October 27, 2021.
  • For more information on the Chegg class action go to: https://bespc.com/cases/CHGG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Women in Science Camps Coming to Central America to Bridge Gender Gap in Science, Technology, Engineering, and Math

Retrieved on: 
Tuesday, January 18, 2022
Woman, Technology, CTE, U.S. Department of Defense Strategy for Operating in Cyberspace, United Nations, United Nations Foundation, Tablet, Intel, COVID-19, Office of Global Partnerships, Caterpillar Inc., United States Department of State, Diplomatic Reception Rooms, U.S. Department of State, Advisory Committee, Student, Government, Female, Department, Transformational Diplomacy, Leadership, Creativity, Movement, Interview, Time, United, Mathematics, Adolescence, STEM, Private sector, Education, Girls Up, Ice, Engineering, Curriculum, Digital divide, Organization, Partnership, Policy, Toy, Tourism, Management, State, Caterpillar, Science, STEAM

From January 24-29, girls will virtually attend six days of programming including insightful discussions, interactive STEAM skills workshops, and leadership-training activities.

Key Points: 
  • From January 24-29, girls will virtually attend six days of programming including insightful discussions, interactive STEAM skills workshops, and leadership-training activities.
  • "At Girl Up, we know the importance of female leadership in every field, especially STEAM fields where women are under-represented.
  • Due to the ongoing COVID-19 pandemic, camp will be held online, with tablets, toolkits, and materials provided by Intel.
  • For more information about the WiSci Girls STEAM Camp, visit: GirlUp.org/WiSci
    Girl Up officials are available for interview during and after the WiSci camp.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA)

Retrieved on: 
Friday, January 14, 2022
Lasso, Alport syndrome, Patient, Alport, News, GPM, Kidney, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Advisory Committee, Safety, NASDAQ, GLOBE, Court, Time, Chronic kidney disease, Lists of schools in England, Risk, Food, AS, FDA, Defendant, DNA methylation, Trial of the century, Investment, Pharmaceutical industry, Animal

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Reata securities during the Class Period, you may move the Court no later than February 18, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against Reata Pharmaceuticals, Inc. (RETA)

Retrieved on: 
Thursday, January 13, 2022
Legal, Professional Services, Securities Exchange Act of 1934, New Drug Application, NDA, Alport syndrome, Patient, Alport, News, Person, Regulation of tobacco by the U.S. Food and Drug Administration, Advisory Committee, Safety, NASDAQ, Reata Pharmaceuticals, Kidney failure, Chronic kidney disease, Company, Therapy, Risk, Food, AS, FDA, DNA methylation, Complaint, Trial of the century, Pharmaceutical industry, Animal

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Reata Pharmaceutical, Inc. (NASDAQ: RETA) securities, and/or sold Reata put options, between November 9, 2020 and December 8, 2021.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Reata Pharmaceutical, Inc. (NASDAQ: RETA) securities, and/or sold Reata put options, between November 9, 2020 and December 8, 2021.
  • Reata is a clinical-stage biopharmaceutical company that focuses on small-molecular therapeutics.
  • If you suffered a loss due to Reata Pharmaceuticals, Inc.'s misconduct, click here .
  • On this news, the Company's stock price fell $25.31, or 46%, to close at $29.11 per share on December 9, 2021.

REATA PHARMACEUTICALS, INC. (NASDAQ: RETA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Retrieved on: 
Thursday, January 13, 2022
Lasso, Securities Exchange Act of 1934, New Drug Application, Alport syndrome, Patient, Alport, The Legal 500, News, Kidney, CKD, Glomerular filtration rate, Labour government, Advisory Committee, Safety, NASDAQ, Company, Trial of the century, LLP, GLOBE, Court, Advertising, EGFR, Chronic kidney disease, Therapy, Risk, AS, FDA, Defendant, District court, Complaint, Reata Pharmaceuticals, Security (finance), Pharmaceutical industry

The lawsuit was filed in the United States District Court for the Eastern District of Texas and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • The lawsuit was filed in the United States District Court for the Eastern District of Texas and alleges violations of the Securities Exchange Act of 1934.
  • Reata is a clinical-stage biopharmaceutical company that focuses on small-molecule therapeutics.
  • The Companys Phase 3 CARDINAL study was purportedly designed to measure the efficacy and safety of bardoxolone.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.